<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Baylor Texas Children's guideline for platelet transfusion for neonatal alloimmune thrombocytopenia (platelet count &lt;100,000/microL)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Baylor Texas Children's guideline for platelet transfusion for neonatal alloimmune thrombocytopenia (platelet count &lt;100,000/microL)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Baylor Texas Children's guideline for platelet transfusion for neonatal alloimmune thrombocytopenia (platelet count &lt;100,000/microL)</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm is based on the clinical practice guideline developed by the Baylor College of Medicine Department of Neonatology for neonatal alloimmune thrombocytopenia.</div><div class="graphic_footnotes">IVIG: intravenous immunoglobulin.<br/>* Major bleeding is defined as a recent episode (within 72 hours) of intracranial bleeding, pulmonary hemorrhage, frank rectal bleeding, and life-threatening bleeding requiring emergency fluid resuscitation or red blood cell transfusion.<br/>¶ Ill-<span style="COLOR: black">appearing includes infants with poor perfusion, lethargy, respiratory distress, and/or apnea. In other centers, the clinical status of the infant does not influence the platelet threshold trigger. <br/>Δ IVIG is administered at a dose of 400 mg/kg per day for three to four days or 1 g/kg per day for 1 to 3 days following platelet </span>transfusion.<br/><font class="lozenge">◊</font> Platelet transfusion is provided if there is evidence of major bleeding, the platelet count falls below 30,000/microL, or the platelet count is below 50,000/microL with deterioration of the clinical status.</div><div id="graphicVersion">Graphic 121752 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
